Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-08-08
2006-08-08
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S673000, C514S151000, C514S659000
Reexamination Certificate
active
07087648
ABSTRACT:
Methods for modulating macrophage proliferation in an individual afflicted with or at risk for a macrophage-associated disease are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including AIDS (HIV)-associated dementia, AIDS-associated non-Hodgkin's lymphoma, and Alzheimer's disease. The invention also provides methods for aiding diagnosis and monitoring therapy of a macrophage-associated non-HIV associated dementia, especially Alzheimer's disease. The invention also provides methods of delaying development of macrophage-associated non-HIV associated dementias, including Alzheimer's disease, which entail administration of an agent which modulates macrophage proliferation.
REFERENCES:
patent: 4847257 (1989-07-01), Hupe et al.
patent: 5037846 (1991-08-01), Saccomano et al.
patent: 5091576 (1992-02-01), Bergeron
patent: 5242947 (1993-09-01), Cherksey et al.
patent: 5460807 (1995-10-01), Cardin et al.
patent: 5498522 (1996-03-01), Porter
patent: 5516807 (1996-05-01), Hupe et al.
patent: 5541230 (1996-07-01), Basu et al.
patent: 5580715 (1996-12-01), McGrath et al.
patent: 5639600 (1997-06-01), McGrath et al.
patent: 5665588 (1997-09-01), Kornbluth
patent: 5672746 (1997-09-01), Nau et al.
patent: 5677350 (1997-10-01), Frydman
patent: 5679682 (1997-10-01), Bergeron
patent: 5880161 (1999-03-01), Basu et al.
patent: 5886051 (1999-03-01), Bergeron, Jr. et al.
patent: 5889061 (1999-03-01), Frydman et al.
patent: 6392098 (2002-05-01), Frydman et al.
patent: 0 162 413 (1985-11-01), None
patent: 0 277 635 (1988-08-01), None
patent: 0 399 519 (1990-11-01), None
patent: 0 399 519 (1990-11-01), None
patent: 0 436 332 (1991-07-01), None
patent: 0 436 332 (1991-07-01), None
patent: 0 436 332 (1991-07-01), None
patent: 60-6348 (1985-02-01), None
patent: 08217670 (1996-08-01), None
patent: WO 92 13548 (1992-08-01), None
patent: WO 93 04036 (1993-03-01), None
patent: WO 93 14782 (1993-08-01), None
patent: WO 96 04019 (1996-02-01), None
patent: WO 98/17624 (1998-04-01), None
patent: WO 99 03823 (1999-01-01), None
Fields et al. “Fields Virology,” vol. 2, 1996, Lippincott Williams & Wilkins, pp. 2418-2419.
Rizzo et al. “Pharmacokinetic profile of Mitoguazone (MGBG) in Patients with AIDS related non-Hodgkin's lymphoma,” 1996, Inventigational New Drug, vol. 14, pp. 227-234.
Von Hoff, “MGBG: Teaching an old drug new tricks,” 1994, Annals of Oncology, vol. 5, pp. 487-493.
Medline Abstract, AN 97070920, Rizzo et al. 1996.
Medline Abstract, AN 95001580, Von Hoff, 1995.
Basu et al.. “The ability of polyamine analogues to induce Z-DNA structure in synthetic polynucleotides in vitro inversely correlates with their effects on cytotoxicity of cis-diaminedichloroplatinum (II) (CDDP) in human brain tumor cell lines” (1996)Anticancer Res.16:39-48.
Bellevue, III et al., “Structural comparison of alkylpolyamine analogues with potent in vitro antitumor or antiparasitic activity” (1996)Bioorg. Med. Chem. Lett.6:2765-2770.
Bergeron et al., “Two polyamine analogs (BE-4-4-4 and BE-4-4-4-4) directly affect growth, survival, and cell cycle progression in two human brain tumor cell lines” (1995)Cancer Chemother. Pharmacol.36:411-417.
Bitonti et al., “Bis(benzyl)polyamine analogs inhibit the growth of chloroquine-resistant human malaria parasites (Plasmodium falciparum) in vitro and in combination with α-difluoromethylornithine cure murine malaria” (1989)Proc. Natl. Acad. Sci. USA86:651-655.
Fogel-Petrovic et al., “Effects of polyamines, polyamine analogs, and inhibitors of protein synthesis on spermidine—spermine N1-acetyltransferase gene expression” (1996)Biochemistry35:14436-14444.
Gabrielian et al., “Effect of leukopenia on experimental post-traumatic retinal detachment” (1993)Curr. Eye. Res.13:1-9.
Greene et al., (1991)Protective Groups in Organic Synthesis,2nd Ed., John Wiley & Sons, Inc., New York. (Table of Contents).
Hibasami et al., “Antitumor effect of a new multienzyme inhibitor of polyamine synthetic pathway, methylglyoxal-bis(cyclopentylamidinohydrazone), against human and mouse leukemia cells” (1989)Cancer Res.49:2065-2068.
Kramer et al., “Use of 4-fluoro-L-ornithine to monitor metabolic flux through the polyamine biosynthetic pathway” (1995)Biochem. Pharmacol.50:1433-1443.
Marton et al., “Polyamines as targets for therapeutic intervention” (1995)Ann Rev. Pharmacol. Toxicol.35:55-91.
McGrath et al., “Identification of a clonal form of HIV in early Kaposi's Sarcoma: Evidence for a novel model of oncogenesis, ‘sequential neoplasia’” (1995)J. Acquired Imm. Def. Syn. Hum. Retro.8:379-385.
Mukhopadhyay et al., “Effects of bis(benzyl)polyamine analogs onLeishmania donovanipromastigotes” (1995)Exper. Parasitology81:39-46.
Porter et al., “Polyamine inhibitors and analogues as potential anticancer agents” (1992)Falk Symposium 62-Polyamines in the Gastrointestinal TractChapter 31, pp. 301-322.
Pulliam et al., “Unique monocyte subset in patients with AIDS dementia” (1997)Lancet349:692-695.
Remington's Pharmaceutical Sciences,18th edition, Mack Publishing (1990) (Table of Contents).
Shiramizu et al., “Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas” (1994)Cancer Res.54:2069-2072.
Bersnstein et al. (1999). “The cellular localization of the L-orinthine decarboxylase polyamine system in normal and diseased central nervous systems,”Progress in Neurobiology57(5):485-505.
Chiang et al. (1996). “Antihuman immunodeficiency virus (HIV-1) activities of inhibitors of polyamine pathways,”J. Biomed. Sci.3(2):78-81.
Kackzmarek et al. (1992). “Inhibitors of polyamine biosynthesis block tumor necrosis factor-induced activation of macrophages,”Cancer Res.52(7):1891-1894.
Lim et al. (Mar. 14, 1995). “MGBG Therapy of relapsed extralymphatic HIV-associated non-hodgkins lymphoma (HIV NHL),”Proc. Annu. Meet. Am. Soc. Clin. Oncol.14:A1274.
Mascolini. (1995). “Oncologists scout new directions for KS and lymphoma therapies,”J. Int. Assoc. Physicians Aids Care1(5):10-14.
Messina et al. (1992). “Polyamine involvement in functional activation of human macrophages,”J. Leukoc. Biol.52(6):585-587.
Miles et al. (Jul. 1, 1996). “Curative therapy for AIDS cancers,”Int. Conf. AIDS.XI(1):28.
Penning et al. (1998). “Sensitization of TNF-induced apoptosis with polyamine synthesis inhibitors in different human and murine tumor cell lines,”Cytokine10 (6):423-431.
N.J. Prakash et al., “Antitumor Activity of Norspermidine, a Structural Homologue of the Natural Polyamine Spermidine,” Anicancer Reseach 8:563-568 (1998).
M. Wojewodzka et al., “Structure-Activity Relationship of Polyamine Derivatives of 1, 3-Dichloroacetone-Thiosemicarbazone: Induction of Metastases and Increase in Sialylation of Murine Lymphoma L5178Y-R Cells,” Chem. Boil. Interactions, 74 (1990) 221-23.
Bozicevic Field & Francis LLP
Francis Carol L.
The Regents of the University of California
Wang Shengjun
LandOfFree
Methods for modulating macrophage proliferation using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulating macrophage proliferation using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulating macrophage proliferation using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3709604